{
  "input": {
    "mode": "build_counterchain",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_acitretin",
          "name": "Acitretin"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_apremilast",
          "name": "Apremilast"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_brodalumab",
          "name": "Brodalumab"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_etanercept",
          "name": "Etanercept"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_guselkumab",
          "name": "Guselkumab"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_ixekizumab",
          "name": "Ixekizumab"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_secukinumab",
          "name": "Secukinumab"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_tildrakizumab",
          "name": "Tildrakizumab"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "tegraph_snapshot": {
      "nodes": [],
      "edges": [],
      "round_index": 2
    },
    "constraints": {
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    }
  },
  "output": {
    "graph_updates": {
      "add_nodes": [
        {
          "id": "n_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_guselkumab",
          "type": "Drug",
          "label": "Guselkumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ixekizumab",
          "type": "Drug",
          "label": "Ixekizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot1",
          "type": "Target",
          "label": "OffTargetInflammation",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp1",
          "type": "Pathway",
          "label": "RiskPathwayChronicInflammation",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv1",
          "type": "Phenotype",
          "label": "AdversechronicCondition",
          "attrs": {
            "agent": "Skeptic"
          }
        }
      ],
      "add_edges": [
        {
          "source": "n_acitretin",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_adalimumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_apremilast",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_brodalumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_etanercept",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_guselkumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_infliximab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_ixekizumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_methotrexate",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_secukinumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_tildrakizumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_ustekinumab",
          "target": "n_ot1",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致的炎症靶点影响"
        },
        {
          "source": "n_ot1",
          "target": "n_rp1",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "与慢性炎症反应相关"
        },
        {
          "source": "n_rp1",
          "target": "n_adv1",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良慢性病理情况"
        },
        {
          "source": "n_adv1",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H3",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H4",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H5",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H6",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H7",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H8",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H9",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H10",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H11",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        },
        {
          "source": "n_adv1",
          "target": "H12",
          "relation": "refutes",
          "weight": 0.85,
          "agent": "Skeptic",
          "rationale": "若该风险成立，将抵消净获益"
        }
      ],
      "merge": [],
      "set_weights": [],
      "conflict_hotspots": [
        {
          "topic": "inflammation vs therapeutic benefit",
          "pro_nodes": [
            "n_acitretin",
            "n_adalimumab",
            "n_apremilast",
            "n_brodalumab",
            "n_etanercept",
            "n_guselkumab",
            "n_infliximab",
            "n_ixekizumab",
            "n_methotrexate",
            "n_secukinumab",
            "n_tildrakizumab",
            "n_ustekinumab"
          ],
          "con_nodes": [
            "n_rp1",
            "n_adv1"
          ],
          "note": "不同药物的炎症抑制效应可能引发长期副作用"
        }
      ]
    },
    "counterclaims": [
      {
        "id": "K1",
        "text": "不同药物的长期副作用可能导致治疗收益下降",
        "confidence": "medium"
      },
      {
        "id": "K2",
        "text": "各类药物对炎症靶点的影响可能导致疾病加重",
        "confidence": "medium"
      }
    ],
    "assumptions_challenged": [
      "治疗是否真正改善长期结局",
      "是否存在创新靶点导致的反向作用"
    ],
    "falsification_tests": [
      "是否存在长期随访研究显示药物使用后的健康结果变化？",
      "不同药物在特定人群中的安全性和有效性数据是否一致？"
    ],
    "next_focus_for_pi": [
      "要求 Proponent 提供针对反向机制的证据支持",
      "对冲突热点进行权重重估"
    ]
  }
}